Cargando…
Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
Drug resistance is a major obstacle to curative cancer therapies, and increased understanding of the molecular events contributing to resistance would enable better prediction of therapy response, as well as contribute to new targets for combination therapy. Here we have analyzed the early molecular...
Autores principales: | Zhou Tran, Yan, Minozada, Rezan, Cao, Xiaofang, Johansson, Henrik J., Branca, Rui M., Seashore-Ludlow, Brinton, Orre, Lukas M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Biochemistry and Molecular Biology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261823/ https://www.ncbi.nlm.nih.gov/pubmed/32234966 http://dx.doi.org/10.1074/mcp.RA120.002036 |
Ejemplares similares
-
Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI
por: Cheong, Hio Teng, et al.
Publicado: (2018) -
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023) -
Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
por: Zhao, Lihao, et al.
Publicado: (2019) -
EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
por: Zhu, Xuan, et al.
Publicado: (2019) -
Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
por: Van De Stadt, Eveline, et al.
Publicado: (2022)